Antihypertensive drug therapy and antioxidant enzyme mRNA levels in spontaneously hypertensive (SHR) rats.
Previous studies have shown that chronic treatment of SHR (spontaneously hypertensive) rats with the antihypertensive drugs captopril, hydralazine and terazosin results in changes in the specific activities of the antioxidant enzymes glutathione peroxidase, catalase and Cu/Zn superoxide dismutase in liver and myocardium. In order to determine if these changes were caused by alterations in the levels of the mRNAs for these enzymes, the tissue levels of the antioxidant enzyme mRNAs have been measured. In myocardium, all three drug treatments increased Cu/Zn superoxide dismutase mRNA but decreased glutathione peroxidase mRNA levels, and in liver, all three drugs changed glutathione peroxidase mRNA levels. In comparison to untreated SHR animals, the levels of all three mRNAs were altered in the myocardium, but not in the liver, of normotensive WKY rats. Comparisons of mRNA levels with tissue enzyme specific activities suggest that tissue antioxidant enzyme expression is, in most cases, regulated by antihypertensive drugs through transcriptional control mechanisms.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002374:Catalase / Q000378:metabolism*; D003300:Copper / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel; D005979:Glutathione Peroxidase / Q000378:metabolism*; D006973:Hypertension / Q000188:drug therapy*; D008099:Liver / Q000201:enzymology; D008297:Male; D009206:Myocardium / Q000201:enzymology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013482:Superoxide Dismutase / Q000378:metabolism*; D015032:Zinc / Q000378:metabolism